Lure Of Niche Drugs Leads India's Cadila To Buy Troubled KV Pharma's Generic Arm For $60 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
With the acquisition of Nesher Pharmaceuticals, Cadila hopes to gain a strong footing in the high-barrier but lucrative controlled substance market, which is estimated at $7 billion.